Samsung BioLogics commits $2bn to CMO business

Samsung has committed $2bn to its biologics custom manufacturing business, Samsung BioLogics. The company, established in 2011, completed construction of its first mammalian cell culture facility in December 2012. The 30,000L facility in the Songdo Free Economic Zone near Seoel, Korea, includes six 5000L reactors, as well as fill and finish and quality control capabilities. The company plans to add another 150,000L of mammalian cell culture manufacturing by 2014 and 40,000 of microbial fermentation by 2016 said TH Kim, President and CEO of Samsung BioLogics, at the JP Morgan conference in San Francisco, earlier this week. Kim said that the business brings together Samsung's construction and manufacturing experience with biologics expertise hired from biotech and other cmos. He said he believes the company can produce biologics at lower cost than competitors and still deliver quality and value for customers.
JP Morgan